Gedeon Richter Pledges New Markets For Teriparatide Biosimilar
Debuted In Three New Markets In Last 12 Months
Executive Summary
Gedeon Richter aims to continue the global roll-out of its teriparatide biosimilar, having enjoyed continued solid growth for the Forsteo rival during the first quarter.
You may also be interested in...
Generics Industry Fails To Match Last Year’s Growth In First Quarter
The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies.
Gedeon Richter Pays $263.5m For Ex-US Rights To Janssen’s Evra
Hungarian firm Gedeon Richter is to expand further its sizeable women’s health portfolio after agreeing to acquire Janssen’s Evra (ethinyl estradiol/norelgestromin) transdermal patch outside of the US for more than a quarter of a billion dollars.
Gedeon Richter Spends Most On Biosimilar R&D
Hungary’s Gedeon Richter enjoyed “rapid sales growth” for its Terrosa teriparatide biosimilar in the first nine months of this year, justifying the firm’s continued advance into biosimilar development.